To study signals of efficacy and safety of a currently available dosage form (IM) of EG-009A in reducing the severity of respiratory disease in patients hospitalized with SARS-CoV-2 virus.
Drug: EG-009A
Administered as an Intramuscular injection
Drug: EG-009A Placebo
Administered as an Intramuscular injection
Drug: Standard of Care
Standard of Care Treatment for COVID-19 Infection
Drug: Dexamethasone
The comparator, Administered as an Intravenous infusion
Inclusion Criteria:
1. Willing and able to provide written informed consent, or with a legal representative
who can provide informed consent, or enrolled under International Conference on
Harmonization (ICH) E6(R2) 4.8.15 emergency use provisions as deemed necessary by the
investigator (age ≥18), or willing and able to provide assent (age ≥12 to <18, where
locally and nationally approved) prior to performing study procedures
2. Patient is aged at least 18 years, enrollment of patients < 65 years old will be
limited to 20% of the total with the first 50% of enrollment conducted solely among
those patients ≥ 55 years old.
3. Patient has SARS-CoV-2 pneumonia from COVID-19 infection of moderate to serious
severity (WHO Ordinal Scale for Clinical Improvement score of 4 or 5)
4. Patient has COVID-19 symptoms ≤ 10 days and at least 1 of the following:
- Radiographic infiltrates by imaging (chest x-ray, CT scan, etc.)
- O2 saturation (SpO2) ≤ 94% on room air
- Requiring supplemental O2 (patients on HFNO ≤ 20 L/min with FiO2 < 0.5 are
allowed), but not requiring mechanical ventilation.
Note: Patients admitted with immediate need for mechanical ventilation are of a severity
too critical for inclusion into this protocol. Patients who are already in the hospital and
have been removed from mechanical ventilation are not eligible.
Exclusion Criteria:
1. Patient has SARS-CoV-2 infection of severity ≥ 6 on COVID-19 WHO Ordinal Scale for
Clinical Improvement or for those subjects who have a WHO Ordinal Scale for Clinical
Improvement score of 5, nasal intermittent positive pressure ventilation (NIPPV) or
requiring HFNO > 20 L/min with FiO2 ≥ 0.5 will be exclusionary.
2. Patient is currently receiving extracorporeal membrane oxygenation, nitric oxide
therapy, or high-frequency oscillatory ventilation
3. Patient is unlikely to survive for > 24 hours from randomization, in the opinion of
the investigator
4. Patient has a history of chronic oxygen use or any pre-existing respiratory condition
that requires intermittent or continuous ambulatory oxygen prior to hospitalization
5. Patient has a history of venous thromboembolism, DVT, or pulmonary embolus
6. Has taken other investigational drugs or participated in any clinical study within 30
days or 5 half-lives (if known) of the investigational drug's PK, PD, or biological
activity (if known), whichever is longer, prior to the first dose of study drug in
this study or is currently participating in another clinical study.